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abatacept, tocilizumab) for the treatment of moderate-to-severe active rheumatoid 
arthritis (RA) in Greece. Methods: A budget impact model was adapted from a third-
party payer perspective (National Organization for Healthcare Services Provision 
[EOPYY]) to evaluate economic aspects of RA treatment over 5 years (2014–2018). 
The model assumed Greek epidemiological data and local reimbursement require-
ments. Two main scenarios, following either a conservative or an increased market 
uptake of CZP in the Greek health care market, were estimated and individually 
compared to the current market trend scenario, which incorporates original biologics 
erosion from biosimilars entry in the coming year. Costs pertaining to drug acquisi-
tion, administration (only for intravenous drugs), and monitoring were included in 
the analysis and corresponded to 2014 costing year. Officially published sources were 
used to derive unit costs. The outcome measures were the annual cost of treatment 
with bDMARD presented as total cost and disaggregated by drug cost, administration 
cost and monitoring cost, as well as the incremental cost savings per year. Results: 
Comparing CZP current versus conservative market uptake scenarios, the total budget 
was slightly increased by € 0.05 million. In contrast, comparing CZP current versus 
increased market uptake scenarios, the total budgetary savings were € 0.23 million. In 
the latter comparison setting, the cost savings were attributed to reduced drug and 
administration costs. More specifically, the greater replacement of an intravenously 
administered bDMARD (infliximab) conduced to the greater reduction of adminis-
tration costs than in the former comparison setting (cost savings: € 0.17 vs. € 0.14 
million). ConClusions: A potential increased use of CZP treatment was shown to 
be associated with cost savings over the next 5 years in Greece.
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objeCtives: About 2.79% of patientswith rheumatoid arthritis (RA) in Russia receive 
TNF-α inhibitors; this value may vary significantly and depends on limitations of 
regional budgets. In this respect, the aim of our study was to conduct a compara-
tive pharmacoeconomic analysis of the most prevalent TNF-α inhibitors in Russian 
patients with rheumatoid arthritis and intolerance or inadequate response to con-
ventional basic therapy. Methods: An pharmacoeconomic model was developed 
based on the data from indirect comparison of anti-TNF-α agents. The model consid-
ers the use of infliximab, etanercept, certulizumab pegol, adalimumab in patients 
with RA who lost response to conventional basic therapy. Cost-effectiveness and 
costs of TNF-α inhibitors for health care budget were estimated. The cost analysis 
included costs of pharmacotherapy. Infliximab and etanercept are included into the 
list of vital and essential medicines and were considered as accepted technologies 
in budget impact analysis: certulizumab pegol and adalimumab were novel tecnolo-
gies in our model. A 24-weeks horizon was adopted. Sensitivity analysis (SA) was 
performed by changing costs of medicines Results: the costs of therapy in certuli-
zumab pegol and etanercept groups were significantly lower than in infliximab and 
adalimumab groups. The cost-effectiveness ratios (CERs) in terms of ACR20 in 24 
weeks were 703 625.00, 587 776.09, and 4 119 260.82 for certulizumab pegol, etaner-
cept and infliximab groups, respectively. The same was observed in case of ACR50 
and ACR70: a strategy of drug use in certulizumab pegol and etanercept groups 
was preferable in comparison with infliximab and adalimumab groups. Budgetary 
costs for health care system were higher in case of infliximab and adalimumab. SA 
confirmed the robustness of the model ConClusions: The study demonstrated 
that certulizumab pegol and etanercept are an economically effective strategy for 
Russian patients with RA and lost response to conventional basic therapy.
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objeCtives: The objective of this study was to determine and compare the resource 
consumption associated with open vs. minimal invasive surgery in patients with 
degenerative spinal disorders in the Russian hospital setting. Methods: Conducted 
cost-analysis was based on Moscow hospital setting, where resource utilization 
associated with average one-level spinal operation was determined through inter-
views with KOLs in spinal surgery. Costs were retrieved from public sources and 
hospital data for the following categories 1) hospital stay; 2) blood transfusion 3) 
consumables (suture materials, hemostatic sponges, disposable instruments); 4) 
time in the operating room; 5) spinal implants/instrumentation; and 6) complica-
tions. Results: The results of the calculations have confirmed MAST economic 
advantages over open surgery (OS). MAST was associated with fewer costs, mainly 
due to shorter stay in intensive care unit (1 vs. 2 days) and general ward (9 vs. 15 
days), no need for blood transfusion and less rate of complications. The difference 
in the duration of surgery, which depends mainly on the speed of approach and 
the installation of implantable structures, is approximately 20 minutes in favor of 
MAST. With the cost of one-hour long surgery at about 6,000 rubles (167$), excluding 
the cost of implantable structures, the use of MAST instead of OS translates into 
savings of 2,000 rubles (56$) per each surgical intervention. As for overall budget 
savings, the use of MAST translates into savings of between 14,783 ($410) and 35,000 
($970) rubles per whole hospital visit, depending on what materials and structures 
are used. ConClusions: The economic evaluation confirms economic domination 
of MAST over OS. Despite initial higher investments, MAST appears to be a cost 
saving alternative to OS, in terms of diminution of actual surgery time, reduction of 
blood transfusion costs, and prevention of post-surgery complications and shorter 
overall length of hospital stay.
validated by a registered nurse. We required 4 data elements to report a patient: date 
when fracture occurred; date when treatment began; date when treatment ended; 
and outcome (healed vs. failed, by clinical and radiological criteria). Data were used 
to calculate: days to treatment (DTT); and days on treatment (DOT). All fresh frac-
tures with DTT, DOT, and outcome are reported. Results: 5,765 patients in the reg-
istry had fresh fracture; 73% of patients (N= 4,190) are reported; 13% of patients were 
lost to follow-up; 11% withdrew or were noncompliant; and 3% died or are miss-
ing outcome. Among compliant patients, HR was 96.2%. Logistic estimates of the 
odds ratio for healing are equivalent for patients aged 30 to 79 years. Nevertheless, 
patients who failed treatment were 4.5 years older than patients who healed (p < 
0.0009). DTT was significantly shorter for patients who healed (p < 0.0001). Data 
show that obesity, smoking, diabetes, vascular insufficiency, osteoporosis, cancer, 
rheumatoid arthritis, and chronic use of NSAIDs reduce HR. ConClusions: LIPUS 
mitigates the effect of age on fracture HR. Patients who used LIPUS had a 96% HR, 
whereas the expected HR averages 93%. Time to treatment was significantly shorter 
among patients who healed (p < 0.0001), suggesting it is beneficial to begin treat-
ment early. Comorbid conditions in conjunction with aging can reduce fracture HR.
PMS13
Pain theraPy for oSteoarthritiS in gerMany: analySiS of SickneSS 
fund claiMS data
Tomeczkowski J.1, Wimmer A.2, Pappert K.2
1Janssen-Cilag GmbH, Neuss, Germany, 2Janssen-Cilag, Neuss, Germany
objeCtives: Using sickness fund claims data, we sought to determine osteoar-
thritis rate, drug compound class, pain therapy prevalence and type of medical 
specialists providing treatment. Methods: A group of company health-sickness 
funds (approx. 2.1 million insured patients in 2010; 2.5 million insured patients in 
2011) was used. Osteoarthritis was identified based on ICD-10 diagnoses (M16.0-9, 
M17.0-5, M17.9, M19.05, M19.25, M19.85, M19.95), then linked to prescriptions using 
the ATC codes: M01A (nonsteroidal anti-inflammatory drugs, NSAIDS), N02B (anal-
gesics and antipyretics), and N02A (opioids). Furthermore, we determined which 
groups of medical specialists prescribed the drugs. Results: Osteoarthritis was 
diagnosed in 7.8% (in 2010) and in 7.1% (in 2011) of patients. In one year, 65.4% of 
patients received a prescription for at least one drug from the analysed ATC codes: 
81.4% of patients received at least one NSAID, 36.4% an analgesic and antipyretic, 
and 27.4% an opioid. For M01A, diclofenac (54%) was most frequently prescribed; 
the proportion of coxibs was 6%. For N02B, 99% of prescriptions were for metami-
zol; 1% for paracetamol. For N02A, most prescriptions were for tramadol (29%) or 
tilidin (28%). General practitioners most frequently prescribed these drugs (42.2% 
[M01A]/46.2% [N02B]/45.9% [N02A]). ConClusions: In Germany in 2010-2011, OA 
prevalence was 7-8%, and associated with analgesic prescriptions for the majority 
of evaluated patients. Diclofenac (NSAIDs, metamizol (analgesics and antipyretics), 
and tramadol or tilidin (opioids) were most frequently prescribed in each group. 
General practitioners were the most frequent painkiller prescribers.
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objeCtives: Ustekinumab was approved for the treatment of psoriatic arthritis (PsA) 
in September 2013. The objective of the study was to estimate the budget impact 
of ustekinumab in the management of PsA in Greece. Methods: A budget impact 
model was developed in Excel 2010 comparing the total PsA treatment costs in the 
current treatment pathway (including golimumab, adalimumab, etanercept and inf-
liximab) with the respective costs of a treatment mix with the inclusion of usteki-
numab. Market share data for the current treatment pathway were based on market 
research. Epidemiology data were taken from the published literature. Due to lack 
of published data on resource use, a 60-field questionnaire was developed in order 
to collect local data relating to the management of PsA in Greece. Two expert panels 
were convened, one with 8 KOL dermatologists and one with 8 KOL rheumatolo-
gists, with the Delphi technique. Unit costs were retrieved from publically available 
sources. The time horizon was five years and the analysis was conducted from the 
Social Insurance Fund perspective. Results: The total number of eligible patients 
(incident and prevalent cases) was estimated to increase from 6,448 in Year 1 to 7,754 
in Year 5. The total cost in the current treatment pathway was estimated to range 
between € 48.4 million in Year 1 and € 20 million in Year 5. The costs in the treatment 
pathway including ustekinumab were € 47.8 and € 18.5 million, in the respective years. 
Therefore, the addition of ustekinumab in the treatment mix can lead to cumulative 
savings for the Social Insurance Funds of € 7.7 million, over the 5-year time horizon. 
This cost reduction is mainly attributed to the less frequent administration of usteki-
numab. ConClusions: Inclusion of ustekinumab in the treatment mix appears to 
be a cost saving treatment option in the management of PsA in Greece.
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objeCtives: To investigate the budgetary impact of increasing the patient share of 
certolizumab pegol (CZP) versus the other recommended biologic disease modifying 
anti-rheumatic drugs (bDMARDs; etanercept, adalimumab, golimumab, infliximab, 
